Any current/future new fundraising through debt or equity?

No specific mention of any current or planned fundraising through debt or equity was made in the document. Company is focusing on large capex investments, particularly Unit 4 expansion, funded through internal cash flows as indicated by mention of flexible cash situation. Ajay Bhardwaj and Gawir Baig highlighted confidence in existing cash position enabling flexibility for potential acquisitions but no definite plans announced. Emphasis is on organic growth and selective inorganic acquisition only if the right opportunity arises; no immediate fundraising tied to these. Overall, no explicit ind

Any current/future capex/capital investment/strategic investment?

Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres. Phase 1 investment of approx. Rs. 1,200 crores over FY27 and FY28, aiming for completion by March 2028. Phase 1 will nearly double custom synthesis capacity (adding 365 kiloliters) and increase fermentation capacity by 50% (adding 100 kiloliters). Unit 2 and Unit 3 expansions are ongoing (currently in CWIP). Post Phase 1, two more phases planned for Unit 4 to further double or triple overall capacity. FY27 capex expected around Rs. 700 crores; subsequent year around Rs. 500 crores. Focus is on becoming future-ready

Future growth expectations in sales/revenue/volumes?

Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade. The company aspires to continue delivering around 20% growth in EBITDA and PAT alongside revenue growth. Recent revenue growth was about 15% due to market adjustments, but EBITDA and PAT grew over 30%. The launch of four new commercial molecules contributes around 8-9% to current revenues, with ramp-up expected over 2-3 years. Capacity expansions, especially Unit 4 (doubling custom synthesis and increasing fermentation capacity by 50%), position the company

Future growth expectations in earnings/operating earnings/profits/EPS?

Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term. EBITDA margins are expected to remain stable around 38-40%, leveraging operating leverage and backward integration gains. PAT growth has been strong (31% YoY in FY26), with aspirations to sustain similar trajectories supported by margin stability. The ramp-up of recently commercialized molecules is expected to take 2-3 years, contributing around 8-9% of current revenues, signaling future earnings growth. Major capex investments (Rs. 700 crores in FY27 and Rs. 500 crores th

Current/ Expected Orderbook/ Pending Orders?

Specialty Ingredients segment operates as a flow business without a traditional order book; products are manufactured and sold continuously to multiple customers across regions. For the CDMO business, order books exist primarily with commercial molecule customers who provide significant lead times, typically up to six months. No specific numeric details on overall pending orders or order book size are provided. The company has around 100 projects in early stages (discovery, development, optimization), with capacity to handle up to 200 projects without constraints. Expansion via Unit 3 and upco

IN US

Sale is live|00:00:00left today

Anthem Biosciences LtdQ1 FY26Pharmaceuticals & Biotechnology

Anthem Biosciences Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹769P/E: 87.5Market Cap: ₹44.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade.
→The company aspires to continue delivering around 20% growth in EBITDA and PAT alongside revenue growth.
→Recent revenue growth was about 15% due to market adjustments, but EBITDA and PAT grew over 30%.
→The launch of four new commercial molecules contributes around 8-9% to current revenues, with ramp-up expected over 2-3 years.
→Capacity expansions, especially Unit 4 (doubling custom synthesis and increasing fermentation capacity by 50%), position the company for future growth.
→The company anticipates broadening relationships with big pharma, expecting growth through new programs and acquisitions of biotech firms.
→Specialty ingredients segment targets ~20% growth.
→Restocking after destocking should positively impact top-line growth going forward.

Margin guidance

Category 3

→Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term.
→EBITDA margins are expected to remain stable around 38-40%, leveraging operating leverage and backward integration gains.
→PAT growth has been strong (31% YoY in FY26), with aspirations to sustain similar trajectories supported by margin stability.
→The ramp-up of recently commercialized molecules is expected to take 2-3 years, contributing around 8-9% of current revenues, signaling future earnings growth.
→Major capex investments (Rs. 700 crores in FY27 and Rs. 500 crores thereafter) in Unit 4 expansion aim to substantially increase capacity and support growth.
→Inorganic growth through acquisitions is being explored but will be undertaken only if quality and strategic fit are met.
→The company expects further growth from increasing biotech funding, new client additions (including big pharma), and technology-driven service enhancements.
→No specific forward-looking EPS guidance was provided, but overall outlook is positive with a focus on sustaining growth and profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any current or planned fundraising through debt or equity was made in the document.
→Company is focusing on large capex investments, particularly Unit 4 expansion, funded through internal cash flows as indicated by mention of flexible cash situation.
→Ajay Bhardwaj and Gawir Baig highlighted confidence in existing cash position enabling flexibility for potential acquisitions but no definite plans announced.
→Emphasis is on organic growth and selective inorganic acquisition only if the right opportunity arises; no immediate fundraising tied to these.
→Overall, no explicit indication of upcoming equity or debt fundraising in the near term.

Order book

Yes

→Specialty Ingredients segment operates as a flow business without a traditional order book; products are manufactured and sold continuously to multiple customers across regions.
→For the CDMO business, order books exist primarily with commercial molecule customers who provide significant lead times, typically up to six months.
→No specific numeric details on overall pending orders or order book size are provided.
→The company has around 100 projects in early stages (discovery, development, optimization), with capacity to handle up to 200 projects without constraints.
→Expansion via Unit 3 and upcoming Unit 4 will increase capacity, supporting future order inflow.
→No near-term guidance on total order book was shared, but management emphasized strong demand and customer trust.
→Specialty Ingredients order momentum recovered with 8% growth in the latest quarter, and further growth expected with dedicated facilities planned.

Capex plans

Yes

→Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres.
→Phase 1 investment of approx. Rs. 1,200 crores over FY27 and FY28, aiming for completion by March 2028.
→Phase 1 will nearly double custom synthesis capacity (adding 365 kiloliters) and increase fermentation capacity by 50% (adding 100 kiloliters).
→Unit 2 and Unit 3 expansions are ongoing (currently in CWIP).
→Post Phase 1, two more phases planned for Unit 4 to further double or triple overall capacity.
→FY27 capex expected around Rs. 700 crores; subsequent year around Rs. 500 crores.
→Focus is on becoming future-ready with increased agility, technology investments, including automation, continuous processing, and green chemistry.
→Open to inorganic growth through acquisitions but only when the right strategic fit is identified.

How does Anthem Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Anthem Biosciences Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Anthem Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio